MARKET

IOVA

IOVA

Iovance Biotherp
NASDAQ
11.25
-0.46
-3.93%
Opening 09:37 04/25 EDT
OPEN
11.49
PREV CLOSE
11.71
HIGH
11.58
LOW
11.21
VOLUME
189.68K
TURNOVER
0
52 WEEK HIGH
18.33
52 WEEK LOW
3.210
MARKET CAP
3.14B
P/E (TTM)
-5.9571
1D
5D
1M
3M
1Y
5Y
AHN Cancer Institute To Offer Groundbreaking Treatment For Metastatic Melanoma; The One-Time Treatment, Made By Iovance Biotherapeutics, Is The First FDA-Approved T-Cell Therapy For Solid Tumors
AHN Cancer Institute is first in western Pennsylvania to offer a first-of-its-kind cellular therapy to treat metastatic melanoma. Amtagvi is the first FDA-approved T-cell therapy for solid tumors. The therapy uses the patient's immune cells to fight the cancer. The American Cancer Society estimates 100,000 new melanomas will be diagnosed in 2024.
Benzinga · 3d ago
Weekly Report: what happened at IOVA last week (0415-0419)?
Weekly Report · 3d ago
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics, Inc. Approved the grant of inducement stock options covering an aggregate of 79,310 shares of Iovance’s common stock to thirty-seven new, non-executive employees on April 18, 2024. The company is a biotechnology company focused on cancer treatments.
Barchart · 5d ago
Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts
Seeking Alpha · 04/16 22:25
Iovance Biotherapeutics Enters Oversold Territory (IOVA)
NASDAQ · 04/15 20:46
Weekly Report: what happened at IOVA last week (0408-0412)?
Weekly Report · 04/15 10:17
Exelixis slips as Barclays downgrades on lack of catalysts
Barclays downgrades cancer drugmaker Exelixis on lack of catalysts. Lead asset cabozantinib faces a patent cliff, analyst says. Barclays sees better upside potential in other companies with similar pipelines. Exelxis shares traded lower on Thursday.
Seeking Alpha · 04/11 14:10
Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results
Seeking Alpha · 04/09 10:05
More
About IOVA
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The Company also marketing Proleukin (aldesleukin), aninterleukin-2, or IL-2, product used in the Amtagvi treatment regimen. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings for solid tumor cancers. Amtagvi and Proleukin are part of a treatment regimen that also includes lymphodepletion. The Company is also developing next generation therapies using TIL, such as genetically modified TIL cell therapy.

Webull offers Iovance Biotherapeutics Inc stock information, including NASDAQ: IOVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IOVA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IOVA stock methods without spending real money on the virtual paper trading platform.